Company Performance Metrics
ImmuneXcite has developed a proprietary platform technology for enhancing the efficacy of therapeutic monoclonal antibodies for oncological and infectious disease targets.
ImmuneXcite was founded based on research originating from the Whitehead Institute at MIT, where a unique carbohydrate was shown to activate neutrophils.
Chemically
linking the carbohydrate to monoclonal antibodies to improve their effector function is a bold concept that has been supported by the Massachusetts Technology Transfer Center, Deshpande Center for Technological Innovation at the Massachusetts Institute of Technology (MIT), the Department of Defense, Massachusetts Life Science Center, National Cancer Institute, and private investor.
Immunexcite, Inc., a biopharmaceutical company, develops monoclonal antibodies for cancer. The company develops monoclonal antibodies by employing its mAbXcite, an immunotherapy platform technology that targets cancer cells for destruction by engaging neutrophils. Immunexcite, Inc. was founded in 2007 and is based in Lexington, Massachusetts.
